<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>334</serviceExecutionTime><Drug id="11136"><DrugName>E-7016</DrugName><DrugSynonyms><Name><Value>GPI-6150</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-6000</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-6488</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-18078</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-15427/C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-16539/C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PARP inhibitors, MGI Pharma</Value></Name><Name><Value>PARS inhibitors, Guilford</Value></Name><Name><Value>PARP-1 inhibitors, Guilford</Value></Name><Name><Value>GPI-18180</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PARP inhibitors, Eisai</Value></Name><Name><Value>E-7016</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPI-21016</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>220938-17-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>433726-76-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20596">Johns Hopkins University</CompanyOriginator><CompaniesSecondary><Company id="15872">Eisai Co Ltd</Company><Company id="16590">MGI GP Inc</Company><Company id="18203">MGI Pharma Inc</Company><Company id="20596">Johns Hopkins University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11136" type="Drug"><TargetEntity id="354440" type="siDrug">GPI-18078</TargetEntity><TargetEntity id="423504" type="siDrug"></TargetEntity><TargetEntity id="769748" type="siDrug">2X-121</TargetEntity><TargetEntity id="252002" type="siDrug">GPI-6000</TargetEntity><TargetEntity id="270851" type="siDrug">GPI-6150</TargetEntity><TargetEntity id="431911" type="siDrug">E-7016</TargetEntity></SourceEntity><SourceEntity id="15872" type="Company"><TargetEntity id="4295876894" type="organizationId">Eisai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16590" type="Company"><TargetEntity id="4295906654" type="organizationId">Mgi Gp Inc</TargetEntity></SourceEntity><SourceEntity id="18203" type="Company"><TargetEntity id="4295907032" type="organizationId">MGI Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="20596" type="Company"><TargetEntity id="5000068265" type="organizationId">Johns Hopkins University</TargetEntity></SourceEntity><SourceEntity id="101" type="ciIndication"><TargetEntity id="10012680" type="MEDDRA"/><TargetEntity id="D003929" type="MeSH"/><TargetEntity id="-1144631334" type="omicsDisease"/><TargetEntity id="169" type="siCondition"/></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"/><TargetEntity id="D013119" type="MeSH"/><TargetEntity id="90058" type="ORPHANET"/><TargetEntity id="-1980782964" type="omicsDisease"/><TargetEntity id="178" type="siCondition"/></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"/><TargetEntity id="D009203" type="MeSH"/><TargetEntity id="-998451372" type="omicsDisease"/><TargetEntity id="226" type="siCondition"/></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"/><TargetEntity id="D019636" type="MeSH"/><TargetEntity id="-1502359765" type="omicsDisease"/><TargetEntity id="160" type="siCondition"/></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity><SourceEntity id="3256" type="ciIndication"><TargetEntity id="10025670" type="MEDDRA"/></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"/><TargetEntity id="708" type="siCondition"/></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="770" type="ciIndication"><TargetEntity id="10019196" type="MEDDRA"/><TargetEntity id="D006259" type="MeSH"/><TargetEntity id="-774444404" type="omicsDisease"/><TargetEntity id="1187" type="siCondition"/></SourceEntity><SourceEntity id="816" type="ciIndication"><TargetEntity id="10040070" type="MEDDRA"/><TargetEntity id="D012772" type="MeSH"/><TargetEntity id="-1178795916" type="omicsDisease"/><TargetEntity id="955" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="38283" type="Action"><TargetEntity id="2212" type="Mechanism">Poly(ADP-ribose) Polymerase 1 (PARP-1; ARTD1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="38286" type="Action"><TargetEntity id="2475" type="Mechanism">Poly(ADP-ribose) Polymerase 2 (PARP-2; ARTD2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2507" type="Action"><TargetEntity id="477" type="Mechanism">NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-07158" type="ciTarget"><TargetEntity id="4412337161423" type="siTarget">Poly [ADP-ribose] polymerase 1</TargetEntity><TargetEntity id="2137" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-07159" type="ciTarget"><TargetEntity id="1260866758100383" type="siTarget">Poly [ADP-ribose] polymerase 2</TargetEntity><TargetEntity id="-1003557309" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="101">Diabetic neuropathy</Indication><Indication id="1258">Spinal cord injury</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="224">Myocardial infarction</Indication><Indication id="233">Neurodegenerative disease</Indication><Indication id="255">Parkinsons disease</Indication><Indication id="3256">Stage III melanoma</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="65">Stroke</Indication><Indication id="651">Cancer</Indication><Indication id="770">Head injury</Indication><Indication id="816">Septic shock</Indication></IndicationsSecondary><ActionsPrimary><Action id="38286">Poly ADP ribose polymerase 2 inhibitor</Action><Action id="38283">Poly ADP ribose polymerase 1 inhibitor</Action><Action id="2507">PARP inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2947">Antiparkinsonian</Action><Action id="1542">Radiosensitizer</Action><Action id="1545">Anticancer</Action><Action id="1586">Anticancer chemosensitizer</Action><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3A</Code><Name>ANTI-EPILEPTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-27T14:40:56.000Z</LastModificationDate><ChangeDateLast>2017-11-28T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15872" linkType="Company"&gt;Eisai Co Ltd&lt;/ulink&gt;, following the acquisition of &lt;ulink linkID="18203" linkType="Company"&gt;MGI Pharma&lt;/ulink&gt; (formerly &lt;ulink linkID="16590" linkType="Company"&gt;Guilford&lt;/ulink&gt;), was developing a capsule formulation of E-7016 (formerly known as GPI-21016; structure shown), the lead from a series of orally-active, brain-penetrable, poly ADP-ribose polymerase (PARP, PAR synthase (PARS)) inhibitors  as a potential chemotherapy and radiotherapy sensitizer [&lt;ulink linkID="626574" linkType="Reference"&gt;626574&lt;/ulink&gt;], [&lt;ulink linkID="871743" linkType="Reference"&gt;871743&lt;/ulink&gt;]. In May 2012, a phase II trial of E-7016 began in  stage III/IV melanoma patients [&lt;ulink linkID="1294397" linkType="Reference"&gt;1294397&lt;/ulink&gt;]. In January 2015, the company stated that development had been discontinued 'in consideration of development priority' [&lt;ulink linkID="1630036" linkType="Reference"&gt;1630036&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Guilford had previously been investigating the compounds for the potential treatment of cerebral and myocardial ischemia. By October 2003, Guilford had been seeking a research partner in Europe, Japan and the US for these indications [&lt;ulink linkID="507610" linkType="reference"&gt;507610&lt;/ulink&gt;].  However, after Guilford's acquisition by MGI Pharma, development in these indications was discontinued in favor of development as chemotherapy and radiotherapy sensitizers [&lt;ulink linkID="626574" linkType="Reference"&gt;626574&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Guilford was previously investigating PARP inhibitors, including GPI-15427, GPI-18078, GPI-6150 and GPI-6000, for the potential treatment of central and peripheral neurological conditions including Parkinson's disease (PD), Alzheimer's disease (AD) and diabetic neuropathy, and as a neuroprotectant in septic shock, head trauma and spinal cord injuries [&lt;ulink linkID="344640" linkType="reference"&gt;344640&lt;/ulink&gt;]. By October 2000, the company was carrying out lead optimization studies [&lt;ulink linkID="370758" linkType="reference"&gt;370758&lt;/ulink&gt;], [&lt;ulink linkID="386300" linkType="reference"&gt;386300&lt;/ulink&gt;], and hoped to select a lead by early 2001 [&lt;ulink linkID="386592" linkType="reference"&gt;386592&lt;/ulink&gt;], [&lt;ulink linkID="413582" linkType="reference"&gt;413582&lt;/ulink&gt;], however by February 2003, Guilford had discontinued its investigations for these indications [&lt;ulink linkID="492938" linkType="reference"&gt;492938&lt;/ulink&gt;], [&lt;ulink linkID="506510" linkType="reference"&gt;506510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CLINICAL DATAE-7016&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2012, a non-randomized, open-label, phase II study (&lt;ulink linkID="87759" linkType="Protocol"&gt;NCT01605162&lt;/ulink&gt;; E7016-A001-201) was initiated in patients with stage IV or unresectable stage III melanoma (expected n = 25) in the US, to assess the safety and efficacy of E-7016 in combiantion with &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt;. In March 2013, recruitment ceased [&lt;ulink linkID="1294397" linkType="Reference"&gt;1294397&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2011, phase I clinical data were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. Patients (n = 12) with advanced solid tumors received E-7016 (4, 8, 16 or 32 mg/kg/day, po, days 1 to 7) alone or in combination with temozolomide (150 mg/m2/day po, days 1 to 5) in a 28-day dosing cycle. An MTD was established at 4 mg/kg. One patient achieved stable disease for &amp;gt; 6 months and two patients showed stable disease for &amp;lt; 6 months.  At that time, a phase II study in advanced melanoma patients was planned [&lt;ulink linkID="1239946" linkType="Reference"&gt;1239946&lt;/ulink&gt;], [&lt;ulink linkID="1239856" linkType="Reference"&gt;1239856&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;subtitle&gt;E-7016&lt;/subtitle&gt;In August 2009, preclinical data were presented at the 238th ACS meeting in Washington DC. E-7016, a 2H-7-oxa-1,2-diaza-benzo[de]anthracen-3-one derivative, and its analogs were found to be effective  as chemo- and radiosensitizers in in vivo models [&lt;ulink linkID="1030870" linkType="Reference"&gt;1030870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER COMPOUNDS&lt;/subtitle&gt;&lt;subtitle&gt;GPI-15427/GPI-18078/GPI18180/&lt;/subtitle&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;Preclinical data on GPI-18180 were presented at the ASCO meeting in Orlando, FL in May 2005. In vitro, GPI-18180 enhanced the inhibition of tumor growth by temozolamide (TMZ) two-to-three-fold. In mice, GPI-18180 enhanced the effect of TMZ against B16 melanoma in the brain [&lt;ulink linkID="652483" linkType="Reference"&gt;652483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on GPI-15427 were presented at the 96th AACR meeting in Anaheim, CA. In the preclinical study GPI-15427 increased the anti-tumor efficacy of temozolomide (TMZ) against a variety of tumor types such as melanoma, lymphoma, glioblastoma multiforme. GPI-15427 achieved oral efficacy against tumors grown intracranially as well as sc in mice. In addition, oral administration of GPI-15427 was well tolerated with an LD50 value of over 1000 mg/kg/day  for 5 days po. At 40 mg/kg/day for 5 days po, GPI-15427 did not exacerbate reduction of white blood cells by the maximal tolerated dose of TMZ in mice. Efficacy of treatments was evaluated by comparing tumor growth in untreated mice, mice treated with irinotecan, or mice treated with irinotecan and GPI 15427. The results indicated GPI-15427 significantly increased antitumor efficacy of irinotecan  [&lt;ulink linkID="602348" linkType="Reference"&gt;602348&lt;/ulink&gt;], [&lt;ulink linkID="602433" linkType="Reference"&gt;602433&lt;/ulink&gt;]. Further data were presented in April 2006 at the AACR meeting in Washington DC. In human colon cancer lines GPI-15427 inhibited cellular PARP activity, PARP-1 and PARP-2,  with IC50 values ranging from 74 to 87 nM, and significantly  enhanced the antiproliferative effects of TMZ (5- to16-fold) and irinotecan (2- to 5-fold). In human colon adenocarcinoma xenografts, GPI-15427 (po) inhibited PARP activity of peripheral blood lymphocytes (PBL) by 60%. Combined with irinotecan and TMZ,  GPI-15427 resulted in tumor regression in all six mice with  LoVo xenografts. In addition, in rats,  GPI-15427-treatment led to protection from severe intestinal injury and diarrhea induced by irinotecan [&lt;ulink linkID="657567" linkType="Reference"&gt;657567&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2004, preclinical data on GPI-15427 were presented at the 95th AACR meeting in Orlando, FL. In a xenograft model of head and neck cancer, iv administration of GPI-15427 enhanced the effect of radiation. When combined with radiation, 10 and 40 mg/kg doses reduced tumor size compared to controls and radiation alone 44 days post-tumor inoculation. Oral doses of GPI-15427 administered 1 h before radiation were also effective. No obvious toxicity was observed with iv or oral administration [&lt;ulink linkID="529197" linkType="reference"&gt;529197&lt;/ulink&gt;], [&lt;ulink linkID="530646" linkType="reference"&gt;530646&lt;/ulink&gt;]. B16 melanoma cells (10(4)) were injected intracranially into male B6D2F1 mice. Tumor bearing mice were treated when neoplastic infiltration of the brain tissue was evident in histological sections. GPI-15427 (10, 40 or 100 mg/kg po) was administered for three or five consecutive days 1 h before &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; (qv; 100 mg/kg ip). Efficacy was evaluated by comparing the survival curves of untreated mice, mice treated with temozolomide, or GPI-15427 alone to the survival curves of mice treated with &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; plus GPI-15427. At all doses tested, no drug-related deaths were observed. Moreover, GPI-15427 plus &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; increased life span of tumor bearing mice compared to untreated mice, mice treated with GPI-15427 or with &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; as single agents [&lt;ulink linkID="529942" linkType="reference"&gt;529942&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003 preclinical data on GPI-15427 were presented at the 94th AACR meeting, Washington, DC. Mice with human glioblastoma multiforme xenografts were administered &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; (100 mg/kg ip) with or without GPI-15427 (1mg). Systemic administration of GPI-15427 shortly before &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; significantly increased life span of tumor bearing mice compared to control or either agent alone [&lt;ulink linkID="498019" linkType="reference"&gt;498019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, preclinical data on GPI-21016 were presented at the  97th AACR meeting in Washington DC. GPI-21016 was found to be a competitive inhibitor of PARP with a Ki value of 50 nM. In a  P388 leukemia model in B6D2F1 mice, GPI-21016 (40 mg/kg ip)  was dosed 15 min pre-, 3-h post- and 6-h post-cisplatin (10 mg/kg ip, q7dx2). GPI-21016 increased the survival benefit of cisplatin treatment by  160% compared to cisplatin alone. In female Wistar rats,  administration of   GPI-21016  (40 mg/kg po) in combination with eight doses of cisplatin (2 mg/kg ip) over 4 weeks,  restored deficits in nerve conductance velocity  induced by cisplatin to 82% [&lt;ulink linkID="657560" linkType="Reference"&gt;657560&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ischemia&lt;/subtitle&gt;In April 2003, evidence of the cardioprotective and anti-inflammatory effects of GPI-15427 were published in FASEB. In a regional heart ischemia model, rats were subjected to occlusion of LAD coronary artery for 30 min followed by 2 h of reperfusion. iv bolus GPI-15427 preischemia plus another iv bolus postischemia exerted cardiac protection in a dose range from 10 to 40 mg/kg.  In a carageenan-induced paw edema model, GPI-15427 (60 mg/kg, iv bolus) markedly reduced the edema by 32%, whereas GPI-6150 given as an ip bolus of 60 mg/kg reduced edema by 28% [&lt;ulink linkID="499823" linkType="reference"&gt;499823&lt;/ulink&gt;]. Research was also published on GPI-18078, which was shown to reduce myocardial ischemia-reperfusion injury in rats and in isolated mouse hearts [&lt;ulink linkID="499824" linkType="reference"&gt;499824&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, preclinical data on GPI-15427/C and GPI-16539/C were presented at the 32nd Neuroscience meeting in Orlando FL. Both compounds were water soluble, and displayed IC50 values of 34 and 76 nM respectively. In the Long Evans rat model of focal cerebral ischemia, administration of both compounds at 40 mg/kg iv pre- and 1 h post-3VO gave a 35% reduction in infarct volume. Significant protection was maintained at lower doses with the MED value being 20 mg/kg iv. Efficacy was lost when the compounds were administered 2 h post-3VO, giving GPI-15427/C and GPI-16539/C a therapeutic window of 1 h [&lt;ulink linkID="468415" linkType="reference"&gt;468415&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GPI-6150&lt;/subtitle&gt;In November 2000, the company confirmed that GPI-6150 was not itself a development candidate, but was being used as a tool to further the program [&lt;ulink linkID="390927" linkType="reference"&gt;390927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;In July 2003, preclinical data on GPI-6150 were presented at the 94th AACR meeting, Washington, DC. To determine the effects of PARP inhibition on gene expression, DNA microarray technology was used to study the profiles of gene expression in the murine macrophage tumor cell line P388D1, in the presence or absence of GPI-6150. Treatment with GPI-6150 led to the downregulation of S100A4 (Mts1) by 4.8-fold at the mRNA level. This suppression was confirmed by Northern blotting and immunohistochemistry, which showed at the protein level that S100A4 was decreased in P388D1 and also MD-MBA-231 and Sk-Br-3, both breast cancer cell line. Most recent results have demonstrated that GPI-6150 treatment strongly reduces invasion of MD-MBA-231 cells through matrigel [&lt;ulink linkID="497464" linkType="reference"&gt;497464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ischemia&lt;/subtitle&gt;In November 2001, data on GPI-6150 were presented at the 31st Neuroscience meeting in San Diego, CA. The right carotid arteries of week-old rat pups were ligated and the pups then received ip either vehicle, 5, 15 or 30 mg/kg of GPI-6150, 5 min after hypoxia which was produced by exposing the animals to 8% oxygen for 2.5 h [&lt;ulink linkID="428426" linkType="reference"&gt;428426&lt;/ulink&gt;]. The size of the right hemisphere was reduced by 15 +/-2.6% in the vehicle group, 5.9 +/-2.8% in the group treated with 5 mg/kg, -0.4 +/- 1.7% in the 15 mg/kg group and 13.3 +/- 3.1% in the 30 mg/kg group. The 15 mg/kg group had a significantly smaller reduction in hemisphere size when compared to the vehicle group [&lt;ulink linkID="428426" linkType="reference"&gt;428426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, results presented at the 30th Society for Neuroscience meeting in New Orleans, LA, showed that GPI-6150 was strongly protective against necrosis in several models, including arthritis, septic shock, streptozotocin-induced diabetes, myocardial and cerebral ischemia and traumatic brain injury [&lt;ulink linkID="390531" linkType="reference"&gt;390531&lt;/ulink&gt;], [&lt;ulink linkID="390633" linkType="reference"&gt;390633&lt;/ulink&gt;]. At 40 mg/kg ip, GPI-6150 demonstrated 75% and 32% efficacy in transient and permanent stroke, respectively [&lt;ulink linkID="392761" linkType="reference"&gt;392761&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical data on GPI-6150 were presented at the Inflammation Research Association Tenth National Meeting (VA, US, September 2000). GPI-6150 selectively and competitively inhibits PARP (IC50 value = 60 nM), although no selectivity was observed between PARP-1 and -2. In carrageenan-induced inflammation, GPI-6150 (3 to 60 mg/kg) dose-dependently reduced paw edema; 60 mg/kg reduced this inflammation by 60%, and histological analysis revealed a reduction in the accumulation of inflammatory cells. With respect to cytokine production, GPI-6150 reduced TNF-alpha and PGE2 levels at 2 h, and IL-1beta levels at 4 h [&lt;ulink linkID="383867" linkType="reference"&gt;383867&lt;/ulink&gt;], [&lt;ulink linkID="384548" linkType="reference"&gt;384548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GPI-6150 demonstrated neuroprotection in rat models of focal ischemia when administered 1 or 2 h after ischemic insult, with a level of protection of approximately 85%. The compound was also active in models of myocardial ischemia, and prevented PARP accumulation following ischemia [&lt;ulink linkID="302377" linkType="reference"&gt;302377&lt;/ulink&gt;], [&lt;ulink linkID="306000" linkType="reference"&gt;306000&lt;/ulink&gt;]. GPI-6150 blocked ADP-ribose polymerization and reduced infarction [&lt;ulink linkID="307022" linkType="reference"&gt;307022&lt;/ulink&gt;]. In studies of hypoxic-ischemic brain injury, in rats treated prior to hypoxia, or 5, 40 or 90 min post-hypoxia, 57%, 52%, 45% and 50% of the brains were scored as normal, which were not significantly different from non-treated animals [&lt;ulink linkID="387480" linkType="reference"&gt;387480&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GPI-6150 was 100-fold selective over other kinases and showed an IC50 value of 100 nM. In the permanent MCAO model, GPI-6150 (40 mg/kg ip) administered 30 min post-occlusion gave a significant reduction (25%) in neuronal damage. In a spontaneously hypertensive rat MCAO model, this treatment gave 40% protection. Measurements were made using TTC histochemistry 24 h post-occlusion [&lt;ulink linkID="344879" linkType="reference"&gt;344879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GPI-6150 competitively inhibited PARP with a Ki value of 60 nM [&lt;ulink linkID="377333" linkType="reference"&gt;377333&lt;/ulink&gt;]. In the P388D1 macrophage cell-based screening assay, GPI-6150 dose-dependently protected from H2O2 cytotoxicity (EC50 value = 2 microM). PARP synthesis was significant, and GPI-6150 treatment eliminated PAR accumulation. At 100 microM, GPI-6150 did not interfere with the repair of N-methyl-N-nitro-N-nitrosoguanidine damaged plasmid DNA in 3T6 fibroblast cells; no selectivity between PARP-1 and PARP-2 was seen [&lt;ulink linkID="388089" linkType="reference"&gt;388089&lt;/ulink&gt;], [&lt;ulink linkID="390531" linkType="reference"&gt;390531&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GPI-6000&lt;/subtitle&gt;By September 1997, GPI-6000, an early lead from the series, was under investigation as a potential treatment for stroke. Data presented at this time demonstrated positive results for GPI-6000 in a rat middle cerebral artery occlusion model of stroke. Administration of GPI-6000 2 h before and after the induced-ischemia produced a significant neuroprotective effect and reduction in the volume of the infarct compared to controls [&lt;ulink linkID="263101" linkType="reference"&gt;263101&lt;/ulink&gt;]. In October 1999, results presented at the 29th Annual Meeting of the Society for Neuroscience indicated that GPI-6000 was efficacious in both transient and permanent occlusion models of stroke [&lt;ulink linkID="345362" linkType="reference"&gt;345362&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ADDITIONAL PRECLINICAL DATA&lt;/subtitle&gt;In March 2004, data on a series of 1,2-dihydro-2,11b-diaza-benzo[de]anthracen-one derivatives were presented at the 227th ACS meeting in Anaheim, CA. One compound (IC50 = 106 nM) showed ~50% reduction in cortical infarct size in the rat MCAO model at 40 mg/kg ip 30 min post-occlusion [&lt;ulink linkID="527019" linkType="reference"&gt;527019&lt;/ulink&gt;], [&lt;ulink linkID="532753" linkType="reference"&gt;532753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2003, preclinical data on a series of aza-5H-phenanthridin-6-one-based PARP1 inhibitors were presented at the 225th ACS meeting in New Orleans, LA. In vivo data showed that one compound was able to reduce cerebral infarct volume in a transient MCAO model by 44% when dosed ip at 80 mg/kg, and to reduce myocardial infarct volume in a rat model by 25% when dosed iv at 80 mg/kg [&lt;ulink linkID="482361" linkType="reference"&gt;482361&lt;/ulink&gt;], [&lt;ulink linkID="517218" linkType="reference"&gt;517218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2002, data on a novel series of imidazobenzodiazepines were presented at the 224th ACS meeting in Boston, MA. This series represented a new class of 'drug-like', water-soluble, potent PARP1 inhibitors, with IC50 values less than 100 nM for the 2-substituted compounds. The most potent compound in the series demonstrated IC50 values of 26 nM, and in the rat transient and permanent MCAO model of brain ischemia, at 40 mg/kg, the compound showed efficacy [&lt;ulink linkID="461797" linkType="reference"&gt;461797&lt;/ulink&gt;], [&lt;ulink linkID="461796" linkType="reference"&gt;461796&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2002, preclinical data on a substituted 5[H]phenanthridin-6-ones series were presented at the 28th National Medicinal Chemistry Symposium in San Diego, CA. Several compounds showed micromolar inhibition of PARP1 and two of the compounds were also active in a rat regional heart ischemia-reperfusion model [&lt;ulink linkID="453916" linkType="reference"&gt;453916&lt;/ulink&gt;]. In March 2004, similar data were presented at the 227th ACS meeting in Anaheim, CA [&lt;ulink linkID="529511" linkType="reference"&gt;529511&lt;/ulink&gt;], [&lt;ulink linkID="529309" linkType="reference"&gt;529309&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By January 2008, Eisai had completed its acquisition of MGI Pharma, through a cash tender for approximately $3.9 billion [&lt;ulink linkID="871743" linkType="Reference"&gt;871743&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Research published in 1995 demonstrated that PARS activity could provide a marker of DNA damage following neurotoxicity [&lt;ulink linkID="459636" linkType="reference"&gt;459636&lt;/ulink&gt;], and that inhibition of PARS prevents nitric oxide-mediated neurotoxicity [&lt;ulink linkID="459638" linkType="reference"&gt;459638&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;PARS is a key enzyme involved in repairing DNA, but when damage is extensive PARS uses too much energy which leads to neuronal damage and death [&lt;ulink linkID="190099" linkType="reference"&gt;190099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Compounds had been licensed exclusively from &lt;ulink linkID="20596" linkType="Company"&gt;Johns Hopkins University&lt;/ulink&gt; by 1994 [&lt;ulink linkID="189959" linkType="reference"&gt;189959&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003, Guilford received a $0.08 million grant from the Ataxia Telangiectasia Children's Project to evaluate the use of PARP inhibitors as chemosensitizers [&lt;ulink linkID="506061" linkType="reference"&gt;506061&lt;/ulink&gt;]. Later in September 2003, Guilford confirmed that it was not using its own funds to support development PARP inhibitors, but grant monies were being used to continue research on the target [&lt;ulink linkID="506510" linkType="reference"&gt;506510&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="770">Head injury</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="255">Parkinsons disease</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1258">Spinal cord injury</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2015-01-30T00:00:00.000Z</StatusDate><Source id="1630036" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2015-01-30T00:00:00.000Z</StatusDate><Source id="1630036" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2015-01-30T00:00:00.000Z</StatusDate><Source id="1630036" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="101">Diabetic neuropathy</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="816">Septic shock</Indication><StatusDate>2002-12-31T00:00:00.000Z</StatusDate><Source id="492938" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3256">Stage III melanoma</Indication><StatusDate>2015-01-30T00:00:00.000Z</StatusDate><Source id="1630036" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="620967" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-01-28T00:00:00.000Z</StatusDate><Source id="871743" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>1994-12-31T00:00:00.000Z</StatusDate><Source id="189959" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="620967" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>1994-12-31T00:00:00.000Z</StatusDate><Source id="189959" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-01-28T00:00:00.000Z</StatusDate><Source id="871743" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2011-02-01T00:00:00.000Z</StatusDate><Source id="1167301" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2012-05-23T00:00:00.000Z</StatusDate><Source id="1294397" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate>2012-05-23T00:00:00.000Z</StatusDate><Source id="1294397" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1429983" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1258">Spinal cord injury</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="816">Septic shock</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="101">Diabetic neuropathy</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="770">Head injury</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="344640" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>1994-12-31T00:00:00.000Z</StatusDate><Source id="189959" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2003-03-13T00:00:00.000Z</StatusDate><Source id="497464" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>2003-09-08T00:00:00.000Z</StatusDate><Source id="507610" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2003-09-08T00:00:00.000Z</StatusDate><Source id="507610" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2003-03-13T00:00:00.000Z</StatusDate><Source id="620967" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01514"><Name>PARP</Name><SwissprotNumbers/></Target><Target id="PTGT-07158"><Name>Poly ADP ribose polymerase 1</Name><SwissprotNumbers><Swissprot>P09874</Swissprot><Swissprot>P11103</Swissprot><Swissprot>P18493</Swissprot><Swissprot>P26446</Swissprot><Swissprot>P27008</Swissprot><Swissprot>P31669</Swissprot><Swissprot>Q08824</Swissprot><Swissprot>Q7EYV7</Swissprot><Swissprot>Q9R152</Swissprot><Swissprot>Q9ZP54</Swissprot><Swissprot>Q9ZSV1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-07159"><Name>Poly ADP ribose polymerase 2</Name><SwissprotNumbers><Swissprot>O50017</Swissprot><Swissprot>O88554</Swissprot><Swissprot>Q11207</Swissprot><Swissprot>Q9UGN5</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1060125">Ataxia Telangiectasia Children's Project Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20596">Johns Hopkins University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc2c(c1)C3CNC(=O)c4c3c(ccc4)O2</Smiles><Smiles>CN1CCN(CC1)c2ccc3c(n2)c4ccccc4c(=O)[nH]3</Smiles><Smiles>c1cc2c3c(c1)Oc4ccc(cc4-c3n[nH]c2=O)CN5CCC(CC5)O</Smiles><Smiles>c1cc2c3c(c1)Oc4ccc(cc4N3CNC2=O)S(=O)=O</Smiles></StructureSmiles><Deals><Deal id="116126" title="Guilford to develop Johns Hopkins' NOS and PARP inhibitors"/><Deal id="121689" title="National Institutes of Health to fund development of Guilford Pharmaceuticals' technologies"/><Deal id="127742" title="Ataxia Telangiectasia Children's Project to award Guilford grant to evalute PARP inhibitors as chemosensitizers "/></Deals><PatentFamilies><PatentFamily id="1013916" number="WO-2009046205" title="PARP Inhibitor compounds, compositions and methods of use"/><PatentFamily id="1539485" number="WO-00116137" title="Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage"/><PatentFamily id="1805650" number="WO-00244183" title="Compounds and their uses"/><PatentFamily id="1913372" number="WO-00191796" title="Methods, compounds and compositions for treating gout"/><PatentFamily id="1977086" number="WO-00039070" title="Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting PARP"/><PatentFamily id="1980193" number="WO-00190077" title="Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses"/><PatentFamily id="2096580" number="WO-00039104" title="Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP"/><PatentFamily id="3079010" number="WO-2015184145" title="Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer"/><PatentFamily id="917112" number="WO-00206240" title="Substituted 4,9-dihydrocyclopenta[IMN] phenanthridine-5-ones, derivatives thereof and their uses"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"/><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>